OSLO, Norway--(BUSINESS WIRE)--The human antibody company, Affitech AS, announced today the appointment of Dr. Sergej Kiprijanov as the Vice President of Discovery Research and Preclinical Development. Joining Affitech at a key stage in the company’s growth, Dr. Kiprijanov brings a wealth of experience in the antibody therapeutic field. Previously CSO of Novoplant GmbH, a German plant biotech company developing antibodies for oral applications, Dr. Kiprijanov was also Head of Research with Affimed Therapeutics AG in Heidelberg, Germany, focusing on engineering human antibodies and antibody fragments for cancer indications.
